Nuzenio

Palbociclib

Palbociclib news intelligence with latest source-attributed stories, timeline, related explainers, connected entities, source diversity, and FAQ.

topic 6 latest news signals 3 publisher sources 100/100 entity strength

Latest news

FDA Approves Palbociclib for HR+, HER2+ Breast Cancer Maintenance - The American Journal of Managed CareThe American Journal of Managed Care · Fri, 07 Aug 2026 18:55:26 GMT Dr Brufsky on the FDA Approval of Gedatolisib Plus Fulvestrant ± Palbociclib in PIK3CA Wild-Type Breast Cancer - OncLiveOncLive · Fri, 07 Aug 2026 03:24:28 GMT FDA Flashback: Breast Cancer Decisions and News From July 2026 - OncLiveOncLive · Thu, 06 Aug 2026 22:03:53 GMT NCCN Guidelines Add Gedatolisib-Based Regimens for Pretreated PIK3CA Wild-Type Advanced Breast Cancer - OncLiveOncLive · Mon, 03 Aug 2026 15:13:18 GMT Gedatolisib/Fulvestrant Earns NCCN Category 1 Listing for HR+/HER2- Breast Cancer - CancerNetworkCancerNetwork · Mon, 03 Aug 2026 12:08:52 GMT Dr Barot on the FDA Approval of Palbociclib/Trastuzumab ± Pertuzumab in HER2+ Breast Cancer - OncLiveOncLive · Fri, 31 Jul 2026 03:40:00 GMT

Timeline

Fri, 07 Aug 2026 18:55:26 GMTFDA Approves Palbociclib for HR+, HER2+ Breast Cancer Maintenance - The American Journal of Managed Care

Fri, 07 Aug 2026 03:24:28 GMTDr Brufsky on the FDA Approval of Gedatolisib Plus Fulvestrant ± Palbociclib in PIK3CA Wild-Type Breast Cancer - OncLive

Thu, 06 Aug 2026 22:03:53 GMTFDA Flashback: Breast Cancer Decisions and News From July 2026 - OncLive

Mon, 03 Aug 2026 15:13:18 GMTNCCN Guidelines Add Gedatolisib-Based Regimens for Pretreated PIK3CA Wild-Type Advanced Breast Cancer - OncLive

Mon, 03 Aug 2026 12:08:52 GMTGedatolisib/Fulvestrant Earns NCCN Category 1 Listing for HR+/HER2- Breast Cancer - CancerNetwork

Fri, 31 Jul 2026 03:40:00 GMTDr Barot on the FDA Approval of Palbociclib/Trastuzumab ± Pertuzumab in HER2+ Breast Cancer - OncLive

Related explainers

ElectionsElection stories need careful handling because polls, turnout, legal challenges, and campaign claims can change quickly.HealthHealth stories help readers understand public-health signals, medical research, hospital systems, medicines, disease updates, and safety guidance.

Connected entities

FDA Approval4 live mentions Wild4 live mentions Breast Cancer Maintenance2 live mentions The American Journal2 live mentions Gedatolisib Plus Fulvestrant2 live mentions Type Breast Cancer2 live mentions OncLive OncLive2 live mentions Breast Cancer Decisions2 live mentions News From July2 live mentions Gedatolisib2 live mentions

FAQ

What does this page track?

Latest RSS headlines, source names, timestamps, related explainers, connected entities, and timeline signals for Palbociclib.

Why might this page be noindex?

Nuzenio only indexes entity pages after enough useful source-attributed coverage and source diversity exists.

Where should readers verify facts?

Open the original publisher links from each story for full reporting, quotes, figures, images, corrections, and updates.

Source diversity

3 distinct publisher/source names are currently connected to this entity page.